683 Capital Management’s Soleno Therapeutics SLNO Stock Holding History

683 Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,000	Closed	-$3.52M	–	156
2025 Q2	$3.52M	Sell	42,000 -8,000	-16%	-$599K	0.23%	89
2025 Q1	$3.57M	Hold	50,000	–	–	0.25%	89
2024 Q4	$2.25M	Sell	50,000 -1,322	-3%	-$68.5K	0.14%	87
2024 Q3	$2.59M	Sell	51,322 -18,678	-27%	-$894K	0.2%	83
2024 Q2	$2.86M	Sell	70,000 -8,000	-10%	-$339K	0.22%	78
2024 Q1	$3.34M	Sell	78,000 -9,000	-10%	-$407K	0.24%	69
2023 Q4	$3.5M	Hold	87,000	–	–	0.29%	69
2023 Q3	$2.57M	Buy	+87,000	New	+$527K	0.2%	80
2020 Q2	–	Sell	-26,667	Closed	-$952K	–	158
2020 Q1	$952K	Sell	26,667 -1,459	-5%	-$62.1K	0.11%	89
2019 Q4	$1.24M	Sell	28,126 -9,813	-26%	-$251K	0.14%	68
2019 Q3	$854K	Hold	37,939	–	–	0.1%	84
2019 Q2	$1.59M	Hold	37,939	–	–	0.14%	86
2019 Q1	$1.17M	Sell	37,939 -18,335	-33%	-$487K	0.11%	90
2018 Q4	$1.44M	Hold	56,274	–	–	0.09%	101
2018 Q3	$1.82M	Hold	56,274	–	–	0.12%	83
2018 Q2	$1.98M	Hold	56,274	–	–	0.13%	84
2018 Q1	$1.53M	Hold	56,274	–	–	0.14%	87
2017 Q4	$1.52M	Buy	56,274 +54,274	+2,714%	+$1.56M	0.13%	99
2017 Q3	$78K	Buy	+2,000	New	+$78.9K	0.01%	115

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

683 Capital Management's SLNO Position: Q3 2025 in Review

683 Capital Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 42,000 shares — an estimated $3.52M sold.

683 Capital Management first reported a position in SLNO in Q3 2017 and held it in 19 quarters. The position peaked at $3.57M in Q1 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

683 Capital Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
683 Capital Management sold 42,000 Soleno Therapeutics shares in Q3 2025, an estimated $3.52M.
683 Capital Management first reported a position in Soleno Therapeutics in Q3 2017 and held it in 19 quarters.
683 Capital Management's Soleno Therapeutics position peaked at $3.57M in Q1 2025.
240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on 683 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.